<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Res Med Sci</journal-id><journal-id journal-id-type="iso-abbrev">J Res Med Sci</journal-id><journal-id journal-id-type="publisher-id">JRMS</journal-id><journal-title-group><journal-title>Journal of Research in Medical Sciences : The Official Journal of Isfahan University of Medical Sciences</journal-title></journal-title-group><issn pub-type="ppub">1735-1995</issn><issn pub-type="epub">1735-7136</issn><publisher><publisher-name>Medknow Publications &#x00026; Media Pvt Ltd</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24381625</article-id><article-id pub-id-type="pmc">3872590</article-id><article-id pub-id-type="publisher-id">JRMS-18-795</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>The effect of levamisole on mortality rate among patients with severe burn injuries</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Fatemi</surname><given-names>Mohammad Javad</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1"/></contrib><contrib contrib-type="author"><name><surname>Salehi</surname><given-names>Hamid</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Akbari</surname><given-names>Hossein</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Alinejad</surname><given-names>Faranak</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Saberi</surname><given-names>Mohsen</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Mousavi</surname><given-names>Seyed Jaber</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Soltani</surname><given-names>Majid</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Taghavi</surname><given-names>Shahrzad</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Payandan</surname><given-names>Hossein</given-names></name><xref ref-type="aff" rid="aff7">7</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Department of Plastic and Reconstructive Surgery, Burn Research Center and Hazrat Fatemeh Hospital, Iran University of Medical Sciences, Tehran, Iran</aff><aff id="aff2"><label>2</label>Department of Surgery, Burn Research Center and Motahari Hospital, Iran University of Medical Sciences, Tehran, Iran</aff><aff id="aff3"><label>3</label>Infectious Disease Specialist, Burn Research Center and Motahari Hospital, Iran University of Medical Sciences, Tehran, Iran</aff><aff id="aff4"><label>4</label>Medicine, Quran and Hadith Research Center and Department of Community Medicine, Baqiyatallah University of Medical Sciences, Tehran, Iran</aff><aff id="aff5"><label>5</label>Department of Community Medicine, Burn Research Center, Iran University of Medical Sciences and Mazandaran University of Medical Sciences, Tehran, Iran</aff><aff id="aff6"><label>6</label>General Physician, Burn Research Center, Iran University of Medical Sciences, Tehran, Iran</aff><aff id="aff7"><label>7</label>Psychologist, Shahid Lavasani Hospital, Social Security Organization, Tehran, Iran</aff><author-notes><corresp id="cor1"><bold>Address for correspondence:</bold> Dr. Mohammad Javad Fatemi, Department of Plastic and Reconstructive Surgery, Burn Research Center and Hazrat Fatemeh Hospital, Iran University of Medical Sciences, Tehran, Iran. E-mail: <email xlink:href="mj-fatemi@tums.ac.ir">mj-fatemi@tums.ac.ir</email></corresp></author-notes><pub-date pub-type="ppub"><month>9</month><year>2013</year></pub-date><volume>18</volume><issue>9</issue><fpage>795</fpage><lpage>800</lpage><history><date date-type="received"><day>28</day><month>2</month><year>2013</year></date><date date-type="rev-recd"><day>11</day><month>8</month><year>2013</year></date><date date-type="accepted"><day>02</day><month>9</month><year>2013</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; Journal of Research in Medical Sciences</copyright-statement><copyright-year>2013</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec id="st1"><title>Background:</title><p>Burn injuries are one of the main causes of mortality and morbidity throughout the world and burn patients have higher chances for infection due to their decreased immune resistance. Levamisole, as an immunomodulation agent, stimulates the immune response against infection.</p></sec><sec id="st2"><title>Materials and Methods:</title><p>This randomized clinical trial was conducted in Motahari Burn Center, Tehran, Iran. Patients who had second- or third-degree burn with involvement of more than 50% of total body surface area (TBSA) were studied. The levamisole group received levamisole tablet, 100 mg per day. Meantime, both the levamisole and control groups received the standard therapy of the Burn Center, based on a standard protocol. Then, the outcome of the patients was evaluated.</p></sec><sec id="st3"><title>Results:</title><p>237 patients entered the study. After excluding 42 patients with inhalation injury, electrical and chemical burns, and the patients who died in the first 72 h, 195 patients remained in the study, including 110 patients in the control group and 85 in the treatment group. The mean age of all patients (between 13 to 64 years) was 33.29 &#x000b1; 11.39 years (Mean &#x000b1; SD), and it was 33.86 &#x000b1; 11.45 years in the control group and 32.57 &#x000b1; 11.32 years in the treatment group. The mean percentage of TBSA burn was 64.50 &#x000b1; 14.34 and 68.58 &#x000b1; 14.55 for the levamisole and control groups, respectively, with the range of 50-100% and 50-95% TBSA. The mortality rate was 68 (61.8%) patients in the control group and 50 (58.8%) patients in the treatment group (<italic>P</italic> = 0.8).</p></sec><sec id="st4"><title>Conclusion:</title><p>According to this study, there was no significant relationship between improvement of mortality and levamisole consumption.</p></sec></abstract><kwd-group><kwd>Burn</kwd><kwd>immunomodulation agent</kwd><kwd>infection</kwd><kwd>levamisole</kwd></kwd-group></article-meta></front><body><sec id="sec1-1"><title>INTRODUCTION</title><p>Treatment of patients with extensive burns remains a major challenge, even with advances in burn care over recent decades.[<xref ref-type="bibr" rid="ref1">1</xref>] Burn injuries are one of the main causes of mortality and morbidity throughout the world, and infections and inhalation injuries are the major causes of death following these injuries.[<xref ref-type="bibr" rid="ref2">2</xref><xref ref-type="bibr" rid="ref3">3</xref><xref ref-type="bibr" rid="ref4">4</xref><xref ref-type="bibr" rid="ref5">5</xref><xref ref-type="bibr" rid="ref6">6</xref><xref ref-type="bibr" rid="ref7">7</xref><xref ref-type="bibr" rid="ref8">8</xref><xref ref-type="bibr" rid="ref9">9</xref>]</p><p>Burns greater than 30% of the total body surface area (TBSA) particularly affect the immune system. Both the innate and adaptive, especially the cellular, immune systems are influenced by the thermal injury,[<xref ref-type="bibr" rid="ref10">10</xref><xref ref-type="bibr" rid="ref11">11</xref><xref ref-type="bibr" rid="ref12">12</xref><xref ref-type="bibr" rid="ref13">13</xref>] and effector mechanisms of nonspecific and specific host defenses are impaired (phagocytosis, chemotaxis, lymphocyte proliferation, antibody production).[<xref ref-type="bibr" rid="ref14">14</xref><xref ref-type="bibr" rid="ref15">15</xref><xref ref-type="bibr" rid="ref16">16</xref><xref ref-type="bibr" rid="ref17">17</xref><xref ref-type="bibr" rid="ref18">18</xref><xref ref-type="bibr" rid="ref19">19</xref>] Severe burn injury also alters the T cell by inducing an imbalance in T helper (Th) cell functions, caused by a phenotypic imbalance in the regulation of Th1 and Th2 immune response.[<xref ref-type="bibr" rid="ref20">20</xref><xref ref-type="bibr" rid="ref21">21</xref><xref ref-type="bibr" rid="ref22">22</xref><xref ref-type="bibr" rid="ref23">23</xref>]</p><p>Therefore, some ways have been developed to improve the immune response and host resistance to septic challenge in thermally injured patients. It has been indicated that consumption of polymyxin B and interleukin-2 can improve resistance against infections in the burned animal models.[<xref ref-type="bibr" rid="ref24">24</xref><xref ref-type="bibr" rid="ref25">25</xref>]</p><p>Levamisole is a derivative of levo isomer of tetramisole, a potent broad-spectrum anthelmintic.[<xref ref-type="bibr" rid="ref26">26</xref><xref ref-type="bibr" rid="ref27">27</xref>] In 1972, its immunomodulation effect was observed. It has been used in many clinical trials to treat many diseases including colon carcinomas, breast cancer, advanced malignant diseases, aphthous stomatitis, childhood nephrotic syndrome, chronic idiopathic urticarial, bacterial infections, and HIV infection with different results.-[<xref ref-type="bibr" rid="ref28">28</xref><xref ref-type="bibr" rid="ref29">29</xref><xref ref-type="bibr" rid="ref30">30</xref><xref ref-type="bibr" rid="ref31">31</xref><xref ref-type="bibr" rid="ref32">32</xref><xref ref-type="bibr" rid="ref33">33</xref><xref ref-type="bibr" rid="ref34">34</xref>] Levamisole stimulates the polymorpho-nuclear lymphocytes (PNL), macrophages, and T lymphocytes, and increases the chemotaxis and proliferation of these cells. Levamisole has an immunostimulant effect by proliferating natural killer cells, which kill T lymphocytes, virus-infected cells, and tumor cells.[<xref ref-type="bibr" rid="ref24">24</xref><xref ref-type="bibr" rid="ref30">30</xref><xref ref-type="bibr" rid="ref35">35</xref><xref ref-type="bibr" rid="ref36">36</xref><xref ref-type="bibr" rid="ref37">37</xref><xref ref-type="bibr" rid="ref38">38</xref><xref ref-type="bibr" rid="ref39">39</xref>] Some studies have also shown that its consumption is almost effective in increasing immunity in burned human and animal models.[<xref ref-type="bibr" rid="ref40">40</xref><xref ref-type="bibr" rid="ref41">41</xref><xref ref-type="bibr" rid="ref42">42</xref><xref ref-type="bibr" rid="ref43">43</xref><xref ref-type="bibr" rid="ref44">44</xref>]</p><p>Because of this modulatory effect of levamisole on immune system and the impairment of this system in burned patients, a study was designed to evaluate the effect of this drug on the mortality of severe second- and third-degree burns over 50% TBSA.</p></sec><sec sec-type="materials|methods" id="sec1-2"><title>MATERIALS AND METHODS</title><p>This randomized parallel-group clinical trial study was conducted in Burn Center, Motahari Hospital, Iran University of Medical Sciences (IUMS), Iran from 7 July 2010 to 7 September 2011. The study was confirmed by the ethical committee of IUMS and was submitted in Iran clinical trial website (<ext-link ext-link-type="uri" xlink:href="http://www.irct.ir">www.irct.ir</ext-link>). Written informed consent was obtained from all the participants (and/or their parents).</p><p>The study population included the patients who referred within 24 h of injuries with second- and/or third-degree thermal burns with more than 50% of TBSA. Patients with chemical burn, electrical burn, inhalation injury, underlying disease, and also the patients who expired within 72 h after hospitalization were excluded from the study. All of the admitted burn patients with 50% and more of TBSA who accepted to participate in the study were enrolled; thus, 237 patients entered the study. At the time of admission, they were randomly assigned to two groups of treatment and control. The levamisole group received levamisole tablet (Poorsina, Tehran, Iran) 100 mg/day until discharge from the hospital or death. Except this part of treatment, patients were treated separately based on their condition by surgeon's decisions.</p><p>Age, sex, etiology, percentage of the burned area, and outcome of each patient were registered.</p><p>The data were analyzed using the independent sample <italic>t</italic>-test, chi-square test, and analysis of variance (ANOVA) by means of SPSS software, with <italic>P</italic> &#x0003c; 0.05 considered as the level of significance.</p></sec><sec sec-type="results" id="sec1-3"><title>RESULTS</title><p>From 7 July 2010 until 7 September 2011, 237 patients aged 13 years and over were enrolled in the study. Data were collected from 133 patients (78.9% males and 21.1% females) in the control group and 104 patients in the treatment group (76.9% males and 23.1% females).</p><p>The mean age of all patients (between 13 to 64 years) was 33.29 &#x000b1; 11.39 years (Mean &#x000b1; SD). It was 33.86 &#x000b1; 11.45 years in the control group and 32.57 &#x000b1; 11.32 years in the treatment group.</p><p>The major causes of burn were gas explosion (38%), flame (39.7%), self-immolation (17.3%), electrical burn (1.7%), and some others. All of them had second- and/or third-degree burn and more than 90% of them had head and neck, trunk, and extremities injury simultaneously.</p><p>After excluding 42 patients with inhalation injury, electrical and chemical burns, and the patients who died in the first 72 h, 195 patients remained in the study, including 110 patients in the control group (81.8% males and 18.2% females) and 85 in the treatment group (77.6% males and 22.4% females).</p><p>The mean percentage of TBSA burn was 64.50 &#x000b1; 14.34 and 68.58 &#x000b1; 14.55 for the levamisole and control groups, respectively, with the range of 50-100% and 50-95% TBSA.</p><p>Mortality among patients was 77 in the control group and 60 of the treatment group. There was no significant difference in mortality in the two groups (<italic>P</italic> = 0.929) [<xref ref-type="table" rid="T1">Table 1</xref>].</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Mortality in levamisole and control groups</p></caption><graphic xlink:href="JRMS-18-795-g001"/></table-wrap><p>In both groups, mortality was significantly more common in female patients (<italic>P</italic> = 0.009 and 0.031, respectively), but mortality was not significantly different in males and females of levamisole and control groups (<italic>P</italic> = 0.83 and 0.61, respectively).</p><p>Levamisole had no effect in reducing mortality in subgroups of different ages (<italic>P</italic> value between 0.479 and 1) [<xref ref-type="table" rid="T2">Table 2</xref>].</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Mortality in age subgroups of levamisole and control patients</p></caption><graphic xlink:href="JRMS-18-795-g002"/></table-wrap><p>Also, the mortality rate was not significantly different between the two groups at different percentages of burns (<italic>P</italic> value between 0.66 and 1) [<xref ref-type="table" rid="T3">Table 3</xref>].</p><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Mortality in different burn percentage of levamisole and control patients</p></caption><graphic xlink:href="JRMS-18-795-g003"/></table-wrap><p>There were significant differences between the two groups in plasma transfusion (<italic>P</italic> = 0.03) and escharotomy surgery (<italic>P</italic> = 0.04). The transfusion and escharotomy indications and need were lower in levamisole group.</p><p>The differences in the debridement number (<italic>P</italic> = 0.2) and graft surgery (<italic>P</italic> = 0.11) were not significant.</p></sec><sec sec-type="discussion" id="sec1-4"><title>DISCUSSION</title><p>Even with advances in burn care over recent decades, the treatment of patients with extensive burns remains a major challenge.[<xref ref-type="bibr" rid="ref1">1</xref><xref ref-type="bibr" rid="ref45">45</xref>] Recent data from the United States indicate 69% mortality among the patients with burns over 70% of TBSA.[<xref ref-type="bibr" rid="ref45">45</xref>]</p><p>The immune system is altered after thermal injury. The severity of immune suppression correlates with the severity of injury. Depressed immune system is one of the major causes of the susceptibility of these patients to infection and sepsis. The humoral immunity is altered, as seen by the decreased levels of immunoglobulins, activation of complement, release of anaphylatoxins, and formation of membrane-attacking complexes. Also, the specific immune response is altered after burn, which includes a depressed ability to produce active rosette-forming cells, depressed stimulation of lymphocyte proliferation, as well as the mixed lymphocyte response. These effects are modulated by the release of kinins, prostaglandins, anaphylatoxins, superoxides, and leukotrienes, all of which can influence the inflammatory response following thermal injury. The immune response is also influenced by some drugs used for other reasons such as steroids, chemotherapeutic agents, and topical agents used for burn wound care.[<xref ref-type="bibr" rid="ref46">46</xref><xref ref-type="bibr" rid="ref47">47</xref><xref ref-type="bibr" rid="ref48">48</xref>]</p><p>Any modulation that can improve the host defense mechanism has a beneficial effect on the rate of sepsis and infection and can decrease the mortality rate of burned patients. The study results of Stinnett <italic>et al</italic>. showed that immunomodulators could be of benefit in burns; however, not all agents are effective.[<xref ref-type="bibr" rid="ref40">40</xref>]</p><p>Levamisole, a synthetic phenylimidazolthiazole, is a potent antihelmintic agent that was first introduced in 1966.[<xref ref-type="bibr" rid="ref1">1</xref><xref ref-type="bibr" rid="ref49">49</xref>]</p><p>After a few years, it was found that this drug had immunotropic properties and seemingly restored inefficient host defense mechanisms.[<xref ref-type="bibr" rid="ref50">50</xref>]</p><p>In many clinical trials and experimental studies, it has been used as an immunomodulation agent for the treatment of cancers, viral and bacterial infections, and aphthous lesions. Moreover, there are many studies about the mechanism of its action over immune system.[<xref ref-type="bibr" rid="ref1">1</xref><xref ref-type="bibr" rid="ref2">2</xref><xref ref-type="bibr" rid="ref3">3</xref><xref ref-type="bibr" rid="ref6">6</xref><xref ref-type="bibr" rid="ref9">9</xref><xref ref-type="bibr" rid="ref18">18</xref><xref ref-type="bibr" rid="ref51">51</xref><xref ref-type="bibr" rid="ref52">52</xref>] It is also useful in the treatment of leprosy, based on an Indian clinical trial.[<xref ref-type="bibr" rid="ref2">2</xref><xref ref-type="bibr" rid="ref49">49</xref>]</p><p>Levamisole has been found effective in the improvement of immune system in some studies and had no effects in some other studies.</p><p>Niedworok <italic>et al</italic>. found that the survival time of the transplants was prolonged significantly by levamisole in healthy rabbits and was diminished in rabbits with burn disease.[<xref ref-type="bibr" rid="ref42">42</xref>]</p><p>In a study on burned animals, it was found that continuous infusion of levamisole treatment significantly increased the inflammatory response.[<xref ref-type="bibr" rid="ref41">41</xref>] The study by Matchin showed that levamisole, antioxidants, and hyperbaric oxygenation facilitated most rapid recovery of the immunological status in burned patients.[<xref ref-type="bibr" rid="ref43">43</xref>]</p><p>In Stinnett <italic>et al</italic>.'s study in animal model, oral administration of levamisole did not reduce mortality in burned guinea pig, which was infected with Pseudomonas microorganism.[<xref ref-type="bibr" rid="ref40">40</xref>]</p><p>The price of levamisole is low and has a few side effects if it is used for a short period of time. The plasma elimination half-life of levamisole is between 3 and 4 h. Levamisole is metabolized by the liver and the metabolites are excreted mainly by the kidneys (70% over 3 days). The elimination half-life of metabolite excretion is approximately 16 h, and 5% is excreted in the feces.[<xref ref-type="bibr" rid="ref53">53</xref>]</p><p>The complications of levamisole include nausea, vomiting, fever, dizziness, headache, skin eruptions, mild anemia, and elevation of liver enzymes. Rare cases of side effects include agranulocytosis, thrombocytopenia, convulsion, and leukoencephalopathy. We did not evaluate the complications of the medication in our patients because the same complications are common in severely burned patients.[<xref ref-type="bibr" rid="ref31">31</xref><xref ref-type="bibr" rid="ref32">32</xref><xref ref-type="bibr" rid="ref54">54</xref><xref ref-type="bibr" rid="ref55">55</xref><xref ref-type="bibr" rid="ref56">56</xref><xref ref-type="bibr" rid="ref57">57</xref>]</p><p>This study indicated no significant relationship between mortality and improvement outcome with levamisole consumption in the patients with third-degree burn with more than 50% of TBSA. This meant that the levamisole group had an equivalent chance for improvement in comparison with the control group.</p><p>Our study has some limitations. First of all, we did not measure any immunological response such as immunoglobulin or immune cellular functions. We only evaluated the mortality as an index of better immunity of the patients and it is not enough.</p><p>Extensively burned patients were selected for this study. These patients had a high mortality rate and the immune modulation may be insufficient for reducing mortality in these patients. Also, the gastrointestinal absorption of the medication was not predictable in the victims of extensive burns and the blood level of levamisole was not measured.</p><p>Although this study showed no beneficial effect of levamisole in extensively burned patients, repetition of the study for less-extensively burned patients and evaluation of blood level of levamizole during the study can clarify the immunomodulation and infection-prevention effects of this medication in thermal injury.</p></sec><sec sec-type="conclusion" id="sec1-5"><title>CONCLUSION</title><p>Based on these findings, it can be suggested that levamisole consumption in second- and third-degree burn patients with the TBSA of more than 50% had no effect on mortality rate. It appears that more randomized trials with less-extensively burned patients are required to evaluate the exact blood level of levamisole in order to fully establish the efficacy of levamisole on the improvement and mortality rate of these patients.</p></sec></body><back><fn-group><fn fn-type="supported-by"><p><bold>Source of Support:</bold> The study received funding for research from Iran University of Medical Sciences</p></fn><fn fn-type="conflict"><p><bold>Conflict of Interest:</bold> None declared.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brusselaers</surname><given-names>N</given-names></name><name><surname>Hoste</surname><given-names>EA</given-names></name><name><surname>Monstrey</surname><given-names>S</given-names></name><name><surname>Colpaert</surname><given-names>KE</given-names></name><name><surname>De Waele</surname><given-names>JJ</given-names></name><name><surname>Vandewoude</surname><given-names>KH</given-names></name><etal/></person-group><article-title>Outcome and changes over time in survival following severe burns from 1985 to 2004</article-title><source>Intensive Care Med</source><year>2005</year><volume>31</volume><fpage>1648</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">16220315</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olaitan</surname><given-names>PB</given-names></name><name><surname>Olaitan</surname><given-names>JO</given-names></name></person-group><article-title>Burns and scalds &#x02014; epidemiology and prevention in a developing country</article-title><source>Niger J Med</source><year>2005</year><volume>14</volume><fpage>9</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">15832636</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Keefe</surname><given-names>GE</given-names></name><name><surname>Hunt</surname><given-names>JL</given-names></name><name><surname>Purdue</surname><given-names>GF</given-names></name></person-group><article-title>An evaluation of risk factors for mortality after burn trauma and the identification of gender-dependent differences in outcomes</article-title><source>J Am Coll Surg</source><year>2001</year><volume>192</volume><fpage>153</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">11220714</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Angus</surname><given-names>DC</given-names></name><name><surname>Wax</surname><given-names>RS</given-names></name></person-group><article-title>Epidemiology of sepsis: An update</article-title><source>Crit Care Med</source><year>2001</year><volume>29</volume><issue>7 Suppl</issue><fpage>S109</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">11445744</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abraham</surname><given-names>E</given-names></name><name><surname>Matthay</surname><given-names>MA</given-names></name><name><surname>Dinarello</surname><given-names>CA</given-names></name><name><surname>Vincent</surname><given-names>JL</given-names></name><name><surname>Cohen</surname><given-names>J</given-names></name><name><surname>Opal</surname><given-names>SM</given-names></name><etal/></person-group><article-title>Consensus conference definitions for sepsis, septic shock, acute lung injury, and acute respiratory distress syndrome: Time for a reevaluation</article-title><source>Crit Care Med</source><year>2000</year><volume>28</volume><fpage>232</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">10667529</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ekenna</surname><given-names>O</given-names></name><name><surname>Sherertz</surname><given-names>RJ</given-names></name><name><surname>Bingham</surname><given-names>H</given-names></name></person-group><article-title>Natural history of bloodstream infections in a burn patient population: The importance of candidemia</article-title><source>Am J Infect Control</source><year>1993</year><volume>21</volume><fpage>189</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">8239049</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bruitt</surname><given-names>BA</given-names><suffix>Jr</suffix></name></person-group><article-title>The diagnosis and treatment of infection in burn patients</article-title><source>Burns</source><year>1984</year><volume>11</volume><fpage>79</fpage><lpage>91</lpage></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Howes</surname><given-names>RM</given-names></name><name><surname>Allen</surname><given-names>RC</given-names></name><name><surname>Su</surname><given-names>CT</given-names></name><name><surname>Hoopes</surname><given-names>JE</given-names></name></person-group><article-title>Altered polymorphonuclear leukocyte bioenergetics in patients with thermal injury</article-title><source>Surg Forum</source><year>1976</year><volume>27</volume><fpage>558</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">1019978</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Howard</surname><given-names>RJ</given-names></name><name><surname>Simmons</surname><given-names>RL</given-names></name></person-group><article-title>Acquired immunologic deficiencies after trauma and surgical procedures</article-title><source>Surg Gynecol Obstet</source><year>1974</year><volume>139</volume><fpage>771</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">4154512</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edwards-Jones</surname><given-names>V</given-names></name><name><surname>Greenwood</surname><given-names>JE</given-names></name></person-group><collab>Manchester Burns Research Group</collab><article-title>What's new in burn microbiology?</article-title><source>Burns</source><year>2003</year><volume>29</volume><fpage>15</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">12543040</pub-id></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Sullivan</surname><given-names>ST</given-names></name><name><surname>O&#x02019;Connor</surname><given-names>TP</given-names></name></person-group><article-title>Immunosuppression following thermal injury: The pathogenesis of immunodysfunction</article-title><source>Br J Plast Surg</source><year>1997</year><volume>50</volume><fpage>615</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">9613404</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lederer</surname><given-names>JA</given-names></name><name><surname>Rodrick</surname><given-names>ML</given-names></name><name><surname>Mannick</surname><given-names>JA</given-names></name></person-group><article-title>The effects of injury on the adaptive immune response</article-title><source>Shock</source><year>1999</year><volume>11</volume><fpage>153</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">10188766</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gennari</surname><given-names>R</given-names></name><name><surname>Alexander</surname><given-names>JW</given-names></name></person-group><article-title>Anti-interleukin-6 antibody treatment improves survival during gut-derived sepsis in a time-dependent manner by enhancing host defense</article-title><source>Crit Care Med Crit Care Med</source><year>1995</year><volume>23</volume><fpage>1945</fpage><lpage>53</lpage></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schl&#x000fc;ter</surname><given-names>B</given-names></name><name><surname>K&#x000f6;nig</surname><given-names>W</given-names></name><name><surname>K&#x000f6;ller</surname><given-names>M</given-names></name><name><surname>Erbs</surname><given-names>G</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>FE</given-names></name></person-group><article-title>Differential regulation of T- and B-lymphocyte activation in severely burned patients</article-title><source>J Trauma</source><year>1991</year><volume>31</volume><fpage>239</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">1825229</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schl&#x000fc;ter</surname><given-names>B</given-names></name><name><surname>K&#x000f6;nig</surname><given-names>W</given-names></name><name><surname>K&#x000f6;ller</surname><given-names>M</given-names></name><name><surname>Erbs</surname><given-names>G</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>FE</given-names></name></person-group><article-title>Studies on B-lymphocyte dysfunctions in severely burned patients</article-title><source>J Trauma</source><year>1990</year><volume>30</volume><fpage>1380</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">2231806</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McIrvine</surname><given-names>AJ</given-names></name><name><surname>O&#x02019;Mahony</surname><given-names>JB</given-names></name><name><surname>Saporoschetz</surname><given-names>I</given-names></name><name><surname>Mannick</surname><given-names>JA</given-names></name></person-group><article-title>Depressed immune response in burn patients: Use of monoclonal antibodies and functional assay to define the role of suppressor cells</article-title><source>Ann Surg</source><year>1982</year><volume>196</volume><fpage>297</fpage><lpage>304</lpage><pub-id pub-id-type="pmid">6214221</pub-id></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakai</surname><given-names>H</given-names></name><name><surname>Daniels</surname><given-names>JC</given-names></name><name><surname>Beathard</surname><given-names>GA</given-names></name><name><surname>Lewis</surname><given-names>SR</given-names></name><name><surname>Lynch</surname><given-names>JB</given-names></name><name><surname>Ritzmann</surname><given-names>SE</given-names></name></person-group><article-title>Mixed lymphocyte culture reaction in patients with acute thermal Burns</article-title><source>J Trauma</source><year>1974</year><volume>14</volume><fpage>53</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">4272243</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calvano</surname><given-names>SE</given-names></name><name><surname>deRiesthal</surname><given-names>HF</given-names></name><name><surname>Marano</surname><given-names>MA</given-names></name><name><surname>Antonacci</surname><given-names>AC</given-names></name></person-group><article-title>The decrease in peripheral blood CD4 and T-cell following thermal injury in human can be accounted for by a concomitant decrease in suppressor-inducer CD4 and T cells as assessed using anti CD4</article-title><source>Clin Immunol Immunopathol</source><year>1988</year><volume>47</volume><fpage>164</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">2450711</pub-id></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ninnemann</surname><given-names>JL</given-names></name></person-group><article-title>Trauma, Sepsis and the immune response</article-title><source>J Burn Care Rehabil</source><year>1987</year><volume>8</volume><fpage>462</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">3325508</pub-id></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>Z</given-names></name><name><surname>Kavanagh</surname><given-names>E</given-names></name><name><surname>Zang</surname><given-names>Y</given-names></name><name><surname>Dolan</surname><given-names>SM</given-names></name><name><surname>Krignovich</surname><given-names>SJ</given-names></name><name><surname>Mannick</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Burn injury promotes antigen-driven Th2-type responses <italic>in vivo</italic></article-title><source>J Immunol</source><year>2003</year><volume>171</volume><fpage>3983</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">14530317</pub-id></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kelly</surname><given-names>JL</given-names></name><name><surname>O&#x02019;Suilleabhain</surname><given-names>CB</given-names></name><name><surname>Soberg</surname><given-names>CC</given-names></name><name><surname>Mannick</surname><given-names>JA</given-names></name><name><surname>Lederer</surname><given-names>JA</given-names></name></person-group><article-title>Severe injury triggers antigen-specific T-helper cell dysfunction</article-title><source>Shock</source><year>1999</year><volume>12</volume><fpage>39</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">10468050</pub-id></element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Sullivan</surname><given-names>ST</given-names></name><name><surname>Lederer</surname><given-names>JA</given-names></name><name><surname>Horgan</surname><given-names>AF</given-names></name><name><surname>Chin</surname><given-names>DH</given-names></name><name><surname>Mannick</surname><given-names>JA</given-names></name><name><surname>Rodrick</surname><given-names>ML</given-names></name></person-group><article-title>Major injury leads to predominance of T helper-2 lymphocyte phenotype and diminished interleukin-12 production associated with decreased resistance to infection</article-title><source>Ann Surg</source><year>1995</year><volume>222</volume><fpage>482</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">7574928</pub-id></element-citation></ref><ref id="ref23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lyons</surname><given-names>A</given-names></name><name><surname>Kelly</surname><given-names>JL</given-names></name><name><surname>Rodrick</surname><given-names>ML</given-names></name><name><surname>Mannick</surname><given-names>JA</given-names></name><name><surname>Lederer</surname><given-names>JA</given-names></name></person-group><article-title>Major injury induces increased production of interleukin-10 by cells of the immune system with a negative impact on resistance to infection. Ann</article-title><source>Ann Surg</source><year>1997</year><volume>226</volume><fpage>450</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">9351713</pub-id></element-citation></ref><ref id="ref24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gough</surname><given-names>DB</given-names></name><name><surname>Moss</surname><given-names>NM</given-names></name><name><surname>Jordan</surname><given-names>A</given-names></name><name><surname>Grbic</surname><given-names>JT</given-names></name><name><surname>Rodrick</surname><given-names>ML</given-names></name><name><surname>Mannick</surname><given-names>JA</given-names></name></person-group><article-title>Recombinant Interleukin-2 improves immune response and host resistance to septic challenge in thermally injured mice</article-title><source>Surgery</source><year>1988</year><volume>104</volume><fpage>292</fpage><lpage>300</lpage><pub-id pub-id-type="pmid">3261049</pub-id></element-citation></ref><ref id="ref25"><label>25</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Alexander</surname><given-names>JW</given-names></name></person-group><year>1989</year><publisher-loc>Texas</publisher-loc><publisher-name>Alteration of opsonic activity after burn injury, proceeding of the 40th Anniversary symposium U.S. Army institute or surgical research. Fortsam Houston</publisher-name><fpage>126</fpage></element-citation></ref><ref id="ref26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Renoux</surname><given-names>G</given-names></name><name><surname>Renoux</surname><given-names>M</given-names></name></person-group><article-title>Modulation of immune reactivity by phenylimidothiazole salts in mice immunized by sheep red blood cells</article-title><source>J Immunol</source><year>1974</year><volume>113</volume><fpage>779</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">4606815</pub-id></element-citation></ref><ref id="ref27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brunner</surname><given-names>CJ</given-names></name><name><surname>Muscoplat</surname><given-names>CC</given-names></name></person-group><article-title>Immunomodulatory effects of Levamisole</article-title><source>J Am Vet Med Assoc</source><year>1980</year><volume>176</volume><fpage>1159</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">7216893</pub-id></element-citation></ref><ref id="ref28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Symoens</surname><given-names>J</given-names></name><name><surname>Rosenthal</surname><given-names>M</given-names></name></person-group><article-title>Levamisole in the modulation of the immune response: The current experimental and clinical state</article-title><source>J Reticuloendothel Soc</source><year>1977</year><volume>21</volume><fpage>175</fpage><lpage>221</lpage><pub-id pub-id-type="pmid">142150</pub-id></element-citation></ref><ref id="ref29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szeto</surname><given-names>C</given-names></name><name><surname>Gillespie</surname><given-names>KM</given-names></name><name><surname>Mathieson</surname><given-names>PW</given-names></name></person-group><article-title>Levamisole induces interleukin-18 and shifts type 1/type2 cytokine balance</article-title><source>Immunology</source><year>2000</year><volume>100</volume><fpage>217</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">10886398</pub-id></element-citation></ref><ref id="ref30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bozi&#x00107;</surname><given-names>F</given-names></name><name><surname>Bili&#x00107;</surname><given-names>V</given-names></name><name><surname>Valpoti&#x00107;</surname><given-names>I</given-names></name></person-group><article-title>Modulating by Levamisole of CD45RA and CD45RC isoforms expression in gut of weaned pigs vaccinated against colibacillosis</article-title><source>J Vet Pharmacol Ther</source><year>2002</year><volume>25</volume><fpage>69</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">11874530</pub-id></element-citation></ref><ref id="ref31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hibi</surname><given-names>D</given-names></name><name><surname>Imazawa</surname><given-names>T</given-names></name><name><surname>Kijima</surname><given-names>A</given-names></name><name><surname>Suzuki</surname><given-names>Y</given-names></name><name><surname>Ishii</surname><given-names>Y</given-names></name><name><surname>Jin</surname><given-names>M</given-names></name><etal/></person-group><article-title>Investigation of carcinogenicity for levamisole administered in the diet to F344 rats</article-title><source>Food Chem Toxicol</source><year>2010</year><volume>48</volume><fpage>3321</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">20837086</pub-id></element-citation></ref><ref id="ref32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boyer</surname><given-names>O</given-names></name><name><surname>Moulder</surname><given-names>JK</given-names></name><name><surname>Grandin</surname><given-names>L</given-names></name><name><surname>Somers</surname><given-names>MJ</given-names></name></person-group><article-title>Short- and long-term efficacy of levamisole as adjunctive therapy in childhood nephrotic syndrome</article-title><source>Pediatr Nephrol</source><year>2008</year><volume>23</volume><fpage>575</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">18204939</pub-id></element-citation></ref><ref id="ref33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ejlertsen</surname><given-names>B</given-names></name><name><surname>Mouridsen</surname><given-names>HT</given-names></name><name><surname>Jensen</surname><given-names>MB</given-names></name><name><surname>Andersen</surname><given-names>J</given-names></name><name><surname>Andersson</surname><given-names>M</given-names></name><name><surname>Kamby</surname><given-names>C</given-names></name><etal/></person-group><article-title>Cyclophosphamide, methotrexate, and fluorouracil; Oral cyclophosphamide; Levamisole; or no adjusant therapy for patients with high-risk, premenopausal breast cancer</article-title><source>Cancer</source><year>2010</year><volume>116</volume><fpage>2081</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">20186830</pub-id></element-citation></ref><ref id="ref34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sayad</surname><given-names>B</given-names></name><name><surname>Alavian</surname><given-names>SM</given-names></name><name><surname>Najafi</surname><given-names>F</given-names></name><name><surname>Soltani</surname><given-names>B</given-names></name><name><surname>Shirvani</surname><given-names>M</given-names></name><name><surname>Janbakhsh</surname><given-names>A</given-names></name><etal/></person-group><article-title>Effects of oral levamisole as an adjuvant to hepatitis b vaccine in HIV/ AIDS patients: A randomized controlled trial</article-title><source>Hepat Mon</source><year>2012</year><volume>12</volume><fpage>e6234</fpage><pub-id pub-id-type="pmid">23087761</pub-id></element-citation></ref><ref id="ref35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bozi&#x00107;</surname><given-names>F</given-names></name><name><surname>Lackovi&#x00107;</surname><given-names>G</given-names></name><name><surname>Kovsca-Janjatovi&#x00107;</surname><given-names>A</given-names></name><name><surname>Smolec</surname><given-names>O</given-names></name><name><surname>Valpoti&#x00107;</surname><given-names>I</given-names></name></person-group><article-title>Levamisole synergizes experimental F4ac+ Escherchiacoli oral vaccine in stimulating ileal peyer's patch T cell in weaned pigs</article-title><source>J Vet Pharmacol Ther</source><year>2006</year><volume>29</volume><fpage>199</fpage><lpage>204</lpage><pub-id pub-id-type="pmid">16669864</pub-id></element-citation></ref><ref id="ref36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janjatovi&#x00107;</surname><given-names>AK</given-names></name><name><surname>Lackovi&#x00107;</surname><given-names>G</given-names></name><name><surname>Bozi&#x00107;</surname><given-names>F</given-names></name><name><surname>Popovi&#x00107;</surname><given-names>M</given-names></name><name><surname>Valpoti&#x00107;</surname><given-names>I</given-names></name></person-group><article-title>Levamisole synergizes proliferation of intestinal IgA+ cells in weaned pigs immunized with vaccine candidate F4ac+ nonenterotoxigenic Esherchia coli strain</article-title><source>J Vet Pharmacol Ther</source><year>2008</year><volume>31</volume><fpage>328</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">18638293</pub-id></element-citation></ref><ref id="ref37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fata</surname><given-names>F</given-names></name><name><surname>Mirza</surname><given-names>A</given-names></name><name><surname>Craig</surname><given-names>G</given-names></name><name><surname>Nair</surname><given-names>S</given-names></name><name><surname>Law</surname><given-names>A</given-names></name><name><surname>Gallagher</surname><given-names>J</given-names></name><etal/></person-group><article-title>Efficacy and toxicity of adjuvant therapy in elderly patients with colon carcinoma: A 10 years experience of the Geisinger Medical center</article-title><source>Cancer</source><year>2002</year><volume>94</volume><fpage>1931</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">11932894</pub-id></element-citation></ref><ref id="ref38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grinev</surname><given-names>MV</given-names></name></person-group><article-title>Cytoreductive surgery as an alternative to palliative operation in oncology</article-title><source>Vestn Khir Im I I Grek</source><year>2002</year><volume>161</volume><fpage>100</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">12638509</pub-id></element-citation></ref><ref id="ref39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karaoglan</surname><given-names>M</given-names></name><name><surname>Demirci</surname><given-names>F</given-names></name><name><surname>Coskun</surname><given-names>Y</given-names></name><name><surname>Karaoglan</surname><given-names>L</given-names></name><name><surname>Bayraktaroglu</surname><given-names>Z</given-names></name><name><surname>Okan</surname><given-names>V</given-names></name><etal/></person-group><article-title>Immunomodulation therapy in children with chronic hepatitis B</article-title><source>J Natl Med Assoc</source><year>2006</year><volume>98</volume><fpage>143</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">16708498</pub-id></element-citation></ref><ref id="ref40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stinnett</surname><given-names>JD</given-names></name><name><surname>Loose</surname><given-names>LD</given-names></name><name><surname>Miskell</surname><given-names>P</given-names></name><name><surname>Tenney</surname><given-names>CL</given-names></name><name><surname>Gonce</surname><given-names>SJ</given-names></name><name><surname>Alexander</surname><given-names>JW</given-names></name></person-group><article-title>Synthetic immunomodulators for prevention of fatal infection in a burned guiea pig model</article-title><source>Ann Surg</source><year>1983</year><volume>198</volume><fpage>53</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">6407411</pub-id></element-citation></ref><ref id="ref41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McManus</surname><given-names>AT</given-names></name></person-group><article-title>Examination of neutrophil function in a rat model of decreased host resistance following burn trauma</article-title><source>Rev Infect Dis</source><year>1983</year><volume>5</volume><issue>Suppl 5</issue><fpage>S898</fpage><lpage>907</lpage><pub-id pub-id-type="pmid">6658285</pub-id></element-citation></ref><ref id="ref42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niedworok</surname><given-names>J</given-names></name><name><surname>Offierska</surname><given-names>M</given-names></name><name><surname>Lambrecht</surname><given-names>W</given-names></name></person-group><article-title>Effect of Levamisole on the survival time of skin Transplants in burn</article-title><source>Z Exp Chir</source><year>1980</year><volume>13</volume><fpage>151</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">6998152</pub-id></element-citation></ref><ref id="ref43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matchin</surname><given-names>EN</given-names></name><name><surname>Atiasov</surname><given-names>NI</given-names></name><name><surname>Zuev</surname><given-names>PD</given-names></name><name><surname>Vinogradova</surname><given-names>GV</given-names></name></person-group><article-title>Methods of correction of humeral and cellular immunity in patients with burns and erosive-ulcerative Levamisole lesions of the gastrointestinal tract</article-title><source>Vestn Khir Im I I Grek</source><year>1990</year><volume>144</volume><fpage>44</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">2173228</pub-id></element-citation></ref><ref id="ref44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Tang</surname><given-names>HT</given-names></name><name><surname>Xia</surname><given-names>ZF</given-names></name><name><surname>Zhu</surname><given-names>SH</given-names></name><name><surname>Ma</surname><given-names>B</given-names></name><name><surname>Wei</surname><given-names>W</given-names></name><etal/></person-group><article-title>Factors affecting survival in adult patients with massive burns</article-title><source>Burns</source><year>2010</year><volume>36</volume><fpage>57</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">19487080</pub-id></element-citation></ref><ref id="ref45"><label>45</label><element-citation publication-type="webpage"><article-title>American Burn Association. National Burn Repository 2005 report</article-title><comment>Available from: <uri xlink:type="simple" xlink:href="http://WWW.ameriburn.org/NBR2005.pdf]08/03/2013">http://WWW.ameriburn.org/NBR2005.pdf] 08/03/2013</uri></comment></element-citation></ref><ref id="ref46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alexander</surname><given-names>JW</given-names></name></person-group><article-title>Serum and Leukocyte lysosomal enzymes: Derangements following severe thermal injury</article-title><source>Arch Surg</source><year>1967</year><volume>95</volume><fpage>482</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">6035471</pub-id></element-citation></ref><ref id="ref47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwacha</surname><given-names>MG</given-names></name><name><surname>Somers</surname><given-names>SD</given-names></name></person-group><article-title>Thermal injury-induced immunosuppression in mice. The role of macrophage-derived reactive nitrogen intermediates</article-title><source>J Leukoc Biol</source><year>1998</year><volume>63</volume><fpage>51</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">9469472</pub-id></element-citation></ref><ref id="ref48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heideman</surname><given-names>M</given-names></name><name><surname>Bengtsson</surname><given-names>A</given-names></name></person-group><article-title>The immunologic response to thermal injury</article-title><source>World J Surg</source><year>1992</year><volume>16</volume><fpage>53</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">1290267</pub-id></element-citation></ref><ref id="ref49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>LY</given-names></name><name><surname>Lin</surname><given-names>YL</given-names></name><name><surname>Chiang</surname><given-names>BL</given-names></name></person-group><article-title>Levamisole enhances immune response by affecting the activation and maturation of human monocyte-derived dendritic cells</article-title><source>British Society for Immunology, Clin Exp Immunol</source><year>2007</year><volume>151</volume><fpage>174</fpage><lpage>81</lpage></element-citation></ref><ref id="ref50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swierenga</surname><given-names>J</given-names></name><name><surname>Gooszen</surname><given-names>HC</given-names></name><name><surname>Vanderschueren</surname><given-names>RG</given-names></name><name><surname>Cosemans</surname><given-names>J</given-names></name><name><surname>Louwagie</surname><given-names>A</given-names></name><name><surname>Stam</surname><given-names>J</given-names></name><etal/></person-group><article-title>Immunopotentiation with levamisole in resectable bronchogenic carcinoma: A double-blind controlled trial, study group for bronchogenic carcinoma</article-title><source>Br Med J</source><year>1975</year><volume>3</volume><fpage>461</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">1098727</pub-id></element-citation></ref><ref id="ref51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hedge</surname><given-names>M</given-names></name><name><surname>Karki</surname><given-names>SS</given-names></name><name><surname>Thomas</surname><given-names>E</given-names></name><name><surname>Kumar</surname><given-names>S</given-names></name><name><surname>Panjamurthy</surname><given-names>K</given-names></name><name><surname>Ranganatha</surname><given-names>SR</given-names></name><etal/></person-group><article-title>Novel levamisole derivative induces extrinsic pathway of apoptosis in cancer cell and inhabits tumor progression in mice</article-title><source>Plos One</source><year>2012</year><volume>7</volume><fpage>1</fpage><lpage>13</lpage></element-citation></ref><ref id="ref52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Ibrahim</surname><given-names>AA</given-names></name><name><surname>Al-kharraz</surname><given-names>SM</given-names></name><name><surname>Al-Sadoon</surname><given-names>DM</given-names></name><name><surname>Al-Madani</surname><given-names>AJ</given-names></name><name><surname>Al-Musallam</surname><given-names>SA</given-names></name></person-group><article-title>Levamisole therapy as a second &#x02014; line immunosuppressive agent in corticosteroid &#x02014; sensitive nephritic Syndrome in children</article-title><source>Saudi J Kidney Dis Transplant</source><year>2003</year><volume>14</volume><fpage>153</fpage><lpage>7</lpage></element-citation></ref><ref id="ref53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Argani</surname><given-names>H</given-names></name><name><surname>Akhtarishojaie</surname><given-names>E</given-names></name></person-group><article-title>Levamizole enhances immune responsiveness to intra-dermal and intra-muscular hepatitis B vaccination in chronic hemodialysis patients</article-title><source>J Immune Based Ther Vaccines</source><year>2006</year><volume>4</volume><fpage>3</fpage><pub-id pub-id-type="pmid">16734912</pub-id></element-citation></ref><ref id="ref54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ching</surname><given-names>JA</given-names></name><name><surname>Smith</surname><given-names>DJ</given-names><suffix>Jr</suffix></name></person-group><article-title>Levamisole-induced necrosis of skin, soft tissue, and bone: Case report and review of literature</article-title><source>J Burn Care Res</source><year>2012</year><volume>33</volume><fpage>e1</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">22051802</pub-id></element-citation></ref><ref id="ref55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Won</surname><given-names>TH</given-names></name><name><surname>Park</surname><given-names>SY</given-names></name><name><surname>Kim</surname><given-names>BS</given-names></name><name><surname>Seo</surname><given-names>PS</given-names></name><name><surname>Park</surname><given-names>SD</given-names></name></person-group><article-title>Levamisole monotherapy for oral lichen planus</article-title><source>Ann Dermatol</source><year>2009</year><volume>21</volume><fpage>250</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">20523798</pub-id></element-citation></ref><ref id="ref56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>N</given-names></name><name><surname>Zhou</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Zhou</surname><given-names>G</given-names></name><name><surname>Zhang</surname><given-names>N</given-names></name><name><surname>Liang</surname><given-names>J</given-names></name></person-group><article-title>Clinical and MRI characteristics of levamisole-induced leukoencephalopathy in 16 patients</article-title><source>J Neuroimaging</source><year>2009</year><volume>19</volume><fpage>326</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">19187474</pub-id></element-citation></ref><ref id="ref57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>KC</given-names></name><name><surname>Ladizinski</surname><given-names>B</given-names></name><name><surname>Federman</surname><given-names>DG</given-names></name></person-group><article-title>Complications associated with use of levamisole-contaminated cocaine: An emerging public health challenge</article-title><source>Mayo Clin Proc</source><year>2012</year><volume>87</volume><fpage>581</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">22677078</pub-id></element-citation></ref></ref-list></back></article>